These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17557084)

  • 21. Drugs and vaccines for the common defense: refining FDA regulation to promote the availability of products to counter biological attacks.
    Javitt GH
    J Contemp Health Law Policy; 2002; 19(1):37-116. PubMed ID: 12733223
    [No Abstract]   [Full Text] [Related]  

  • 22. Getting SMART (submission management and review tracking) drug review in the computer age.
    Flieger K
    FDA Consum; 1995 Oct; 29(8):6-9. PubMed ID: 10151839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA notifications. FDA issues public health advisory about ESAs.
    AIDS Alert; 2007 May; 22(5):57-8. PubMed ID: 17580370
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. It is time for food and drug administration reform.
    Guharoy R
    Arch Intern Med; 2010 Apr; 170(8):737. PubMed ID: 20421564
    [No Abstract]   [Full Text] [Related]  

  • 26. Effort to privatize drug reviews grows.
    Scott L
    Mod Healthc; 1995 Jun; 25(26):54. PubMed ID: 10143746
    [No Abstract]   [Full Text] [Related]  

  • 27. Remarks of the Lead Deputy Commissioner of the Food and Drug Administration.
    Friedman MA
    Food Drug Law J; 1998; 53(1):19-23. PubMed ID: 11795333
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug advisory committees. Getting outside advice for close calls.
    Farley D
    FDA Consum; 1995 Mar; 29(2):23-6. PubMed ID: 10172354
    [No Abstract]   [Full Text] [Related]  

  • 29. The special treatment.
    Osborne R
    Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
    [No Abstract]   [Full Text] [Related]  

  • 30. Managed care outlook. Oncologists: FDA needs to speed up approval of cancer-fighting drugs.
    Manag Care; 2002 Jun; 11(6):56. PubMed ID: 12098877
    [No Abstract]   [Full Text] [Related]  

  • 31. Uncertainty surrounds cancer vaccine review at FDA.
    Fox JL
    Nat Biotechnol; 2007 Aug; 25(8):827-8. PubMed ID: 17687346
    [No Abstract]   [Full Text] [Related]  

  • 32. From laboratory to medicine cabinet.
    Caring; 1992 Nov; 11(11):16-20. PubMed ID: 10121248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BIO and biogenerics.
    Feldbaum CB
    Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
    [No Abstract]   [Full Text] [Related]  

  • 34. How are drugs approved? Part 3. The stages of drug development.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Mar; 46(3):17-20. PubMed ID: 18416270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Looking for solid ground along the Critical Path.
    Ratner M
    Nat Biotechnol; 2006 Aug; 24(8):885-7. PubMed ID: 16900118
    [No Abstract]   [Full Text] [Related]  

  • 36. A turbulent year at the agency.
    Ratner M
    Nat Biotechnol; 2006 Feb; 24(2):145-51. PubMed ID: 16465153
    [No Abstract]   [Full Text] [Related]  

  • 37. The FDA's new oncology office.
    Pazdur R
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):612-3. PubMed ID: 16167044
    [No Abstract]   [Full Text] [Related]  

  • 38. Changes for ESAs.
    Spalding BJ
    Nat Biotechnol; 2008 May; 26(5):483. PubMed ID: 18464763
    [No Abstract]   [Full Text] [Related]  

  • 39. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 40. Remarks by the Commissioner of Food and Drugs.
    Kessler DA
    Food Drug Law J; 1996; 51(2):207-15. PubMed ID: 11817358
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.